Incannex Healthcare Ltd (IHL)

0.430
-0.010(-2.27%)
  • Volume:
    2,154,591
  • Bid/Ask:
    0.430/0.435
  • Day's Range:
    0.420 - 0.450

IHL Overview

Prev. Close
0.44
Day's Range
0.42-0.45
Revenue
1.52M
Open
0.44
52 wk Range
0.235-0.755
EPS
-0.01
Volume
2,154,591
Market Cap
557.06M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
7,366,555
P/E Ratio
-
Beta
1.97
1-Year Change
61.11%
Shares Outstanding
1,280,602,321
Next Earnings Date
-
What is your sentiment on Incannex Healthcare?
or
Market is currently closed. Voting is open during market hours.

Incannex Healthcare Ltd News

Incannex Healthcare Ltd Company Profile

Incannex Healthcare Ltd Company Profile

Employees
0
Market
Australia

Incannex Healthcare Limited is an Australia-based company. It is a clinical stage pharmaceutical development company. The Company is engaged in developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Its product candidate IHL-42X is developing a combination of acetazolamide and dronabinol to reduce the apnea hypopnea index (AHI), IHL-216A is a combination of isoflurane and CBD to prevent development of traumatic brain injury (TBI)/concussion, HL-675A comprises a combination of hydroxychloroquine and CBD in prevention and treatment of inflammatory lung conditions (ARDS, COPD, asthma, and bronchitis), rheumatoid arthritis and inflammatory bowel diseases and Psi-GAD is providing Psychedelic-assisted psychotherapy for Generalized Anxiety Disorder (GAD).

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellBuy
Technical IndicatorsStrong BuySellStrong SellSellBuy
SummaryBuySellStrong SellStrong SellBuy
  • The emerging next big pharma will multiple clinic trials with unmet need will global potential sales in the $B’s. Recent success with OSA phase 2 results.
    0